Pieces of the puzzle: The first fragment-based approach was used to target cytochrome P450 enzymes (CYPs) for drug development (see scheme). The experiments provide new insights into the binding site of the essential Mycobacterium tuberculosis CYP121 enzyme, and resulted in a promising novel lead compound based on fragment merging.
|Number of pages||6|
|Journal||Angewandte Chemie - International Edition|
|Early online date||13 Aug 2012|
|Publication status||Published - 10 Sep 2012|